Genesis Prize Co-Founder Stan Polovets Steps Down as Chairman of Anchiano Therapeutics after Company Posts 630% Return in 12 Months
The Genesis Prize Foundation announced that Stan Polovets has stepped down as chairman of Anchiano Therapeutics following its merger with Chemomab Therapeutics on March 16, now trading as CMMB.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
The Genesis Prize Foundation announced that Stan Polovets has stepped down as chairman of Anchiano Therapeutics following its merger with Chemomab Therapeutics on March 16, now trading as CMMB. During Polovets' tenure, Anchiano's stock surged 630%, outperforming many peers. The merger aims to focus on innovative therapies for inflammation and fibrosis, backed by significant investor financing. Polovets expressed gratitude for the management team's efforts, highlighting the company’s potential for further success in the biotech space.
Positive
- Anchiano's stock appreciated 630% during Polovets' chairmanship.
- The merger with Chemomab expands the company's operations into high unmet medical needs.
- Secured additional financing from prominent healthcare-focused investors.
Negative
- None.
Details
News Market Reaction – CMMB
The recorded move for CMMB in the trading session of this news was -9.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 22, 2021 /PRNewswire/ -- The Genesis Prize Foundation today announced that its co-founder Stan Polovets has stepped down as chairman of the board of Anchiano Therapeutics (NASDAQ ANCN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer.
Mr. Polovets' decision not to remain on the Board of Directors follows the merger between Anchiano and Israel-based Chemomab Therapeutics, announced on Monday, March 16. The merged company, which is now traded on NASDAQ under the ticker CMMB, will expand its scope of operations and focus on discovering and developing innovative therapeutics for conditions with high unmet needs that involve inflammation and fibrosis.
During approximately one year that Mr. Polovets served as chairman of Anchiano, the company's stock appreciated
Stan Polovets said: "I am very proud of the work of the senior management of Anchiano, whose talent, hard work and dedication made such a phenomenal outcome possible. I am particularly grateful to Anchiano's CEO Neil Cohen and CFO Andrew Fine, our counsel Aaron Lampert, and our excellent advisors from Cooley and Oppenheimer. I am certain that the combined company, with its outstanding leadership and strong investor base, will enjoy even greater success." As part of the merger, Chemomab received additional financing from prominent healthcare-focused investors Cormorant Asset Management, OrbiMed, Peter Thiel and Christian Angermayer's Presight Capital and Apeiron Investment Group.
The largest investor in ANCH was Access Industries, a company controlled by prominent industrialist and philanthropist Len Blavantik. Over the past twenty years, Mr. Polovets has worked on a number of ventures with Mr. Blavatnik, including TNK-BP, one of the largest oil companies in the world. Created with the original investment of
View original content to download multimedia:http://www.prnewswire.com/news-releases/genesis-prize-co-founder-stan-polovets-steps-down-as-chairman-of-anchiano-therapeutics-after-company-posts-630-return-in-12-months-301252616.html
SOURCE The Genesis Prize Foundation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.